Increased Serum Insulin-like Growth Factor-1 Levels are Associated with Prolonged Response to Dasatinib-based Regimens in Metastatic Prostate Cancer

BACKGROUND: Dasatinib, an inhibitor of Src-family kinases, combined with docetaxel in men with castrate-resistant prostate cancer (CRPC), affects bone turnover markers in a phase I/II clinical trial in metastatic CRPC. Only a subset of men benefit from this therapy, and predictive markers are lackin...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Dayyani, Farshid, Varkaris, Andreas, Araujo, John C., Song, Jian H., Chatterji, Tanushree, Trudel, Geralyn C., Logothetis, Christopher J., Gallick, Gary E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4013833/
https://ncbi.nlm.nih.gov/pubmed/23371521
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pros.22645
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller